Familial clustering of HTLV-I infection in southeastern Italy

Diabetic Patients With Newly Diagnosed Chronic Myeloid Leukemia: TKI Choice and Early Adverse Events. A Real-Life Survey Within the Italian Chronic Myeloid Leukemia Network.

European journal of haematology·2026

Real-World Efficacy and Safety of Gemtuzumab Ozogamycin (GO) and 3 + 7 regimen in fit newly diagnosed Acute Myeloid Leukemia (AML) patients. A Retrospective multicenter study of "Rete Ematologica Pugliese" (REP).

Leukemia research reports·2025

Treatment outcomes in sinonasal aspergillosis in dogs in the United Kingdom: 436 cases (2011-2021).

The Journal of small animal practice·2025

Choice of Frontline Tyrosine-Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A "Campus CML" Study.

European journal of haematology·2024

Diagnostic findings in sinonasal aspergillosis in dogs in the United Kingdom: 475 cases (2011-2021).

The Journal of small animal practice·2024

Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma: initial follow-up of an Italian multicentre retrospective clinical experience by 'Rete Ematologica Pugliese'.

Annals of hematology·2022

8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India.

Lancet (London, England)·2026

Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.

Lancet (London, England)·2026

A trembling detour to the diagnosis of encephalitis: a neuroborreliosis case report.

Lancet (London, England)·2026

Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

Lancet (London, England)·2026

Efficacy and safety of garetosmab, an activin A-blocking antibody, in fibrodysplasia ossificans progressiva (OPTIMA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet (London, England)·2026

Cognitive impairment in idiopathic intracranial hypertension: A conceptual framework and therapeutic implications.

Surgical neurology international·2026

Junctional plakoglobin regulates intestinal epithelial cell proliferation via MAPK/ERK signaling.

Cell communication and signaling : CCS·2026

Validity and Reliability of the Turkish IPREA-18: A Psychometric Study in Intensive Care Unit Patients.

Journal of nursing measurement·2026

Immunometabolic alterations in post-traumatic stress disorder.

Brain, behavior, and immunity·2026

Oral delivery of recombinant Lactococcus lactis expressing an IL-23 inhibitor as a potential therapeutic strategy for experimental colitis.

Drug delivery·2026

Contact behavior and serological evidence of influenza reinfection across three post-COVID-19 pandemic seasons in a nationwide German cohort.

Infection·2026

Related Experiment Videos

Familial clustering of HTLV-I infection in southeastern Italy

Related Concept Videos

Diabetic Patients With Newly Diagnosed Chronic Myeloid Leukemia: TKI Choice and Early Adverse Events. A Real-Life Survey Within the Italian Chronic Myeloid Leukemia Network.

Real-World Efficacy and Safety of Gemtuzumab Ozogamycin (GO) and 3 + 7 regimen in fit newly diagnosed Acute Myeloid Leukemia (AML) patients. A Retrospective multicenter study of "Rete Ematologica Pugliese" (REP).

Treatment outcomes in sinonasal aspergillosis in dogs in the United Kingdom: 436 cases (2011-2021).

Choice of Frontline Tyrosine-Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A "Campus CML" Study.

Diagnostic findings in sinonasal aspergillosis in dogs in the United Kingdom: 475 cases (2011-2021).

Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma: initial follow-up of an Italian multicentre retrospective clinical experience by 'Rete Ematologica Pugliese'.

8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India.

Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.

A trembling detour to the diagnosis of encephalitis: a neuroborreliosis case report.

Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

Efficacy and safety of garetosmab, an activin A-blocking antibody, in fibrodysplasia ossificans progressiva (OPTIMA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Cognitive impairment in idiopathic intracranial hypertension: A conceptual framework and therapeutic implications.

Junctional plakoglobin regulates intestinal epithelial cell proliferation via MAPK/ERK signaling.

Validity and Reliability of the Turkish IPREA-18: A Psychometric Study in Intensive Care Unit Patients.

Immunometabolic alterations in post-traumatic stress disorder.

Oral delivery of recombinant Lactococcus lactis expressing an IL-23 inhibitor as a potential therapeutic strategy for experimental colitis.

Contact behavior and serological evidence of influenza reinfection across three post-COVID-19 pandemic seasons in a nationwide German cohort.

Related Experiment Videos

Familial clustering of HTLV-I infection in southeastern Italy

Related Concept Videos

Related Articles